世界の進行性運動失調無力症治療市場予測2023-2029:タンパク質ミスフォールディング、幹細胞治療

【英語タイトル】Syndrome Progressive Ataxia Weakness Disorder Treatment Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料(MMG23FB2420)・商品コード:MMG23FB2420
・発行会社(調査会社):Market Monitor Global
・発行日:2023年2月
・ページ数:68
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥481,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥625,300見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥721,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の進行性運動失調無力症治療市場規模と予測を収録しています。・世界の進行性運動失調無力症治療市場:売上、2018年-2023年、2024年-2029年
・世界の進行性運動失調無力症治療市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の進行性運動失調無力症治療市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「タンパク質ミスフォールディング」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

進行性運動失調無力症治療のグローバル主要企業は、Acorda Therapeutics、American Regent、Baxter International、Biogen Idec、Bristol-Myers Squibb、Cadila Healthcare、Eli Lilly and Company、Glaxosmilthkline、Sanofi、Roche Holding、Pfizer、Novartis AGなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、進行性運動失調無力症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の進行性運動失調無力症治療市場:タイプ別、2018年-2023年、2024年-2029年
世界の進行性運動失調無力症治療市場:タイプ別市場シェア、2022年
・タンパク質ミスフォールディング、幹細胞治療

世界の進行性運動失調無力症治療市場:用途別、2018年-2023年、2024年-2029年
世界の進行性運動失調無力症治療市場:用途別市場シェア、2022年
・医療検査室、治療センター、その他

世界の進行性運動失調無力症治療市場:地域・国別、2018年-2023年、2024年-2029年
世界の進行性運動失調無力症治療市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における進行性運動失調無力症治療のグローバル売上、2018年-2023年
・主要企業における進行性運動失調無力症治療のグローバル売上シェア、2022年
・主要企業における進行性運動失調無力症治療のグローバル販売量、2018年-2023年
・主要企業における進行性運動失調無力症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Acorda Therapeutics、American Regent、Baxter International、Biogen Idec、Bristol-Myers Squibb、Cadila Healthcare、Eli Lilly and Company、Glaxosmilthkline、Sanofi、Roche Holding、Pfizer、Novartis AG

*************************************************************

・調査・分析レポートの概要
進行性運動失調無力症治療市場の定義
市場セグメント
世界の進行性運動失調無力症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の進行性運動失調無力症治療市場規模
世界の進行性運動失調無力症治療市場規模:2022年 VS 2029年
世界の進行性運動失調無力症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの進行性運動失調無力症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の進行性運動失調無力症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:タンパク質ミスフォールディング、幹細胞治療
進行性運動失調無力症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:医療検査室、治療センター、その他
進行性運動失調無力症治療の用途別グローバル売上・予測

・地域別市場分析
地域別進行性運動失調無力症治療市場規模 2022年と2029年
地域別進行性運動失調無力症治療売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Acorda Therapeutics、American Regent、Baxter International、Biogen Idec、Bristol-Myers Squibb、Cadila Healthcare、Eli Lilly and Company、Glaxosmilthkline、Sanofi、Roche Holding、Pfizer、Novartis AG

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Syndrome Progressive Ataxia Weakness Disorder Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Overall Market Size
2.1 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size: 2022 VS 2029
2.2 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Syndrome Progressive Ataxia Weakness Disorder Treatment Players in Global Market
3.2 Top Global Syndrome Progressive Ataxia Weakness Disorder Treatment Companies Ranked by Revenue
3.3 Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue by Companies
3.4 Top 3 and Top 5 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Syndrome Progressive Ataxia Weakness Disorder Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Syndrome Progressive Ataxia Weakness Disorder Treatment Players in Global Market
3.6.1 List of Global Tier 1 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size Markets, 2022 & 2029
4.1.2 Protein Misfolding
4.1.3 Stem Cell Therapies
4.2 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue & Forecasts
4.2.1 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2023
4.2.2 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2024-2029
4.2.3 By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2022 & 2029
5.1.2 Medical Laboratory
5.1.3 Treatment Center
5.1.4 Others
5.2 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue & Forecasts
5.2.1 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2023
5.2.2 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2024-2029
5.2.3 By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2022 & 2029
6.2 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue & Forecasts
6.2.1 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2023
6.2.2 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2024-2029
6.2.3 By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.3.2 US Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.3.3 Canada Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.3.4 Mexico Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.4.2 Germany Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.3 France Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.4 U.K. Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.5 Italy Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.6 Russia Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.4.8 Benelux Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.5.2 China Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.3 Japan Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.4 South Korea Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.5.6 India Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.6.2 Brazil Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.6.3 Argentina Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029
6.7.2 Turkey Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7.3 Israel Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
6.7.5 UAE Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size, 2018-2029
7 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies Profiles
7.1 Acorda Therapeutics
7.1.1 Acorda Therapeutics Company Summary
7.1.2 Acorda Therapeutics Business Overview
7.1.3 Acorda Therapeutics Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.1.4 Acorda Therapeutics Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.1.5 Acorda Therapeutics Key News & Latest Developments
7.2 American Regent
7.2.1 American Regent Company Summary
7.2.2 American Regent Business Overview
7.2.3 American Regent Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.2.4 American Regent Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.2.5 American Regent Key News & Latest Developments
7.3 Baxter International
7.3.1 Baxter International Company Summary
7.3.2 Baxter International Business Overview
7.3.3 Baxter International Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.3.4 Baxter International Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.3.5 Baxter International Key News & Latest Developments
7.4 Biogen Idec
7.4.1 Biogen Idec Company Summary
7.4.2 Biogen Idec Business Overview
7.4.3 Biogen Idec Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.4.4 Biogen Idec Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.4.5 Biogen Idec Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.5.4 Bristol-Myers Squibb Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Cadila Healthcare
7.6.1 Cadila Healthcare Company Summary
7.6.2 Cadila Healthcare Business Overview
7.6.3 Cadila Healthcare Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.6.4 Cadila Healthcare Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.6.5 Cadila Healthcare Key News & Latest Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Company Summary
7.7.2 Eli Lilly and Company Business Overview
7.7.3 Eli Lilly and Company Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.7.4 Eli Lilly and Company Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.7.5 Eli Lilly and Company Key News & Latest Developments
7.8 Glaxosmilthkline
7.8.1 Glaxosmilthkline Company Summary
7.8.2 Glaxosmilthkline Business Overview
7.8.3 Glaxosmilthkline Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.8.4 Glaxosmilthkline Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.8.5 Glaxosmilthkline Key News & Latest Developments
7.9 Sanofi
7.9.1 Sanofi Company Summary
7.9.2 Sanofi Business Overview
7.9.3 Sanofi Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.9.4 Sanofi Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.9.5 Sanofi Key News & Latest Developments
7.10 Roche Holding
7.10.1 Roche Holding Company Summary
7.10.2 Roche Holding Business Overview
7.10.3 Roche Holding Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.10.4 Roche Holding Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.10.5 Roche Holding Key News & Latest Developments
7.11 Pfizer
7.11.1 Pfizer Company Summary
7.11.2 Pfizer Business Overview
7.11.3 Pfizer Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.11.4 Pfizer Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.11.5 Pfizer Key News & Latest Developments
7.12 Novartis AG
7.12.1 Novartis AG Company Summary
7.12.2 Novartis AG Business Overview
7.12.3 Novartis AG Syndrome Progressive Ataxia Weakness Disorder Treatment Major Product Offerings
7.12.4 Novartis AG Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global Market (2018-2023)
7.12.5 Novartis AG Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Syndrome Progressive Ataxia Weakness Disorder Treatment Market Opportunities & Trends in Global Market
Table 2. Syndrome Progressive Ataxia Weakness Disorder Treatment Market Drivers in Global Market
Table 3. Syndrome Progressive Ataxia Weakness Disorder Treatment Market Restraints in Global Market
Table 4. Key Players of Syndrome Progressive Ataxia Weakness Disorder Treatment in Global Market
Table 5. Top Syndrome Progressive Ataxia Weakness Disorder Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Syndrome Progressive Ataxia Weakness Disorder Treatment Product Type
Table 9. List of Global Tier 1 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Syndrome Progressive Ataxia Weakness Disorder Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2024-2029
Table 30. Acorda Therapeutics Company Summary
Table 31. Acorda Therapeutics Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 32. Acorda Therapeutics Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Acorda Therapeutics Key News & Latest Developments
Table 34. American Regent Company Summary
Table 35. American Regent Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 36. American Regent Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. American Regent Key News & Latest Developments
Table 38. Baxter International Company Summary
Table 39. Baxter International Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 40. Baxter International Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Baxter International Key News & Latest Developments
Table 42. Biogen Idec Company Summary
Table 43. Biogen Idec Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 44. Biogen Idec Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Biogen Idec Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company Summary
Table 47. Bristol-Myers Squibb Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 48. Bristol-Myers Squibb Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Bristol-Myers Squibb Key News & Latest Developments
Table 50. Cadila Healthcare Company Summary
Table 51. Cadila Healthcare Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 52. Cadila Healthcare Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Cadila Healthcare Key News & Latest Developments
Table 54. Eli Lilly and Company Company Summary
Table 55. Eli Lilly and Company Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 56. Eli Lilly and Company Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Eli Lilly and Company Key News & Latest Developments
Table 58. Glaxosmilthkline Company Summary
Table 59. Glaxosmilthkline Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 60. Glaxosmilthkline Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Glaxosmilthkline Key News & Latest Developments
Table 62. Sanofi Company Summary
Table 63. Sanofi Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 64. Sanofi Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Sanofi Key News & Latest Developments
Table 66. Roche Holding Company Summary
Table 67. Roche Holding Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 68. Roche Holding Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 69. Roche Holding Key News & Latest Developments
Table 70. Pfizer Company Summary
Table 71. Pfizer Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 72. Pfizer Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 73. Pfizer Key News & Latest Developments
Table 74. Novartis AG Company Summary
Table 75. Novartis AG Syndrome Progressive Ataxia Weakness Disorder Treatment Product Offerings
Table 76. Novartis AG Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue (US$, Mn) & (2018-2023)
Table 77. Novartis AG Key News & Latest Developments
List of Figures
Figure 1. Syndrome Progressive Ataxia Weakness Disorder Treatment Segment by Type in 2022
Figure 2. Syndrome Progressive Ataxia Weakness Disorder Treatment Segment by Application in 2022
Figure 3. Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Syndrome Progressive Ataxia Weakness Disorder Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue in 2022
Figure 8. By Type - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 16. US Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 28. China Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. Acorda Therapeutics Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. American Regent Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Baxter International Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Biogen Idec Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bristol-Myers Squibb Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Cadila Healthcare Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Eli Lilly and Company Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Glaxosmilthkline Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Sanofi Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Roche Holding Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Pfizer Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Novartis AG Syndrome Progressive Ataxia Weakness Disorder Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



★調査レポート[世界の進行性運動失調無力症治療市場予測2023-2029:タンパク質ミスフォールディング、幹細胞治療] (コード:MMG23FB2420)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の進行性運動失調無力症治療市場予測2023-2029:タンパク質ミスフォールディング、幹細胞治療]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆